🟠 Moderate Evidence
Post-exposure prophylaxis with doxycycline in high-risk populations is associated with an increased prevalence of drug-resistant mutations in Mycoplasma genitalium, according to research published in the International Journal of Infectious Diseases in September 2026. The finding raises concerns about the sustainability of current sexually transmitted infection (STI) prevention strategies and suggests that widespread prophylactic use may inadvertently drive resistance emergence.
Key takeaways
- Doxycycline post-exposure prophylaxis correlates with higher prevalence of resistance-associated mutations in Mycoplasma genitalium strains
- The study was conducted among high-risk populations where STI burden is elevated
- These findings may influence clinical guidelines for STI prevention and treatment strategies
Study at a Glance
| Source | International Journal of Infectious Diseases |
| Study type | Observational analysis |
| Sample | High-risk populations with documented M. genitalium exposure |
| Population | High-risk individuals |
| Country | Taiwan |
Resistance emergence risk factors in STI prevention
Relative pressure from prophylactic antibiotic use in high-risk populations
Source: International Journal of Infectious Diseases, September 2026 | Georgian Medical Journal News
The resistance paradox in STI prevention
A study led by researchers at National Taiwan University, including Dr. Chien-Ching Hung and colleagues, examined how prophylactic doxycycline use correlates with resistance mutations in Mycoplasma genitalium—an increasingly common cause of urogenital infection that has already developed fluoroquinolone resistance in many settings. The authors analysed samples from high-risk individuals and documented the prevalence of resistance-associated mutations in bacterial isolates.
Mycoplasma genitalium has become a public health concern in part because of its limited treatment options and rapid emergence of resistance. The World Health Organization has flagged this pathogen as a priority for antimicrobial resistance surveillance. Doxycycline, a tetracycline antibiotic, has been used both therapeutically and prophylactically to reduce STI acquisition in high-risk populations such as men who have sex with men and sex workers.
Post-exposure prophylaxis with doxycycline is associated with increased prevalence of drug-resistant Mycoplasma genitalium mutations in high-risk populations.
— Dr. Chien-Ching Hung and colleagues, National Taiwan University (International Journal of Infectious Diseases, September 2026)
What drives resistance emergence during prophylaxis
The mechanism underlying this finding reflects a classical epidemiological principle: antimicrobial agents create selective pressure that favours survival of resistant strains. When doxycycline is used prophylactically—particularly in populations with high STI transmission rates—susceptible bacteria are eliminated while any pre-existing resistant variants have a growth advantage. Suboptimal adherence, variable bioavailability, or intermittent dosing regimens can further contribute to subinhibitory drug levels that encourage resistance development.
This poses a particular challenge in settings where M. genitalium prevalence is elevated. According to studies cited in published literature on STI epidemiology, incidence rates in high-risk groups can reach 10–15% annually or higher. In such contexts, the balance between prevention benefit and resistance risk must be carefully weighed. The implications align with broader concerns about antimicrobial resistance raised by the US Centers for Disease Control and Prevention (CDC) regarding overuse of prophylactic antibiotics.
For more on antimicrobial stewardship in sexual health, see our coverage of Pharmacy & Prescribing updates.
Clinical and public health implications
The study’s findings suggest that current prophylactic regimens may need reassessment. While post-exposure prophylaxis has demonstrated efficacy in reducing STI incidence, the emergence of resistance could eventually undermine this benefit. Clinical practice guidelines may need to incorporate resistance surveillance data and consider alternative or more targeted prophylaxis approaches.
One implication is the potential value of rapid diagnostic testing to identify resistant strains early, allowing clinicians to tailor treatment and adjust prophylaxis recommendations at the population level. Another is the need for better understanding of which high-risk populations benefit most from prophylaxis versus those where surveillance and early treatment might be more appropriate. These questions align with the Health Policy imperative to balance individual prevention with population-level antimicrobial stewardship.
What this means
Frequently asked questions
What is Mycoplasma genitalium and why is it a concern?
Mycoplasma genitalium is a bacterium that causes urogenital infection and is sexually transmitted. It is increasingly recognised as a cause of pelvic inflammatory disease and is notable for its rapid development of antibiotic resistance, particularly to fluoroquinolones. This limits treatment options and increases the public health burden in affected populations.
How does prophylactic doxycycline work, and why might it promote resistance?
Prophylactic doxycycline is given to high-risk individuals to prevent STI acquisition by killing bacteria during or shortly after exposure. However, repeated use creates selective pressure that favours resistant bacterial strains. Over time, resistant variants accumulate in the population, reducing the effectiveness of prophylaxis and complicating future treatment options.
What should people in high-risk groups do if they currently use doxycycline prophylaxis?
Continue discussions with your healthcare provider about the continued benefits and risks of your current regimen. Ensure strict adherence to dosing instructions if prophylaxis is recommended. Regular STI screening and rapid diagnosis remain important tools for early detection and treatment, regardless of prophylaxis status. Do not stop prophylaxis without medical advice.
As antimicrobial resistance continues to reshape treatment landscapes across infectious diseases, the challenge posed by resistant Mycoplasma genitalium exemplifies a broader tension in modern medicine: the need to prevent disease through effective tools while preserving the long-term utility of those tools through judicious use. Future STI prevention strategies will likely require integrated surveillance, personalised risk assessment, and continued research into resistance mechanisms and alternative prophylactic approaches.
Was this article helpful?
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
